Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 133, Issue 2, Pages 703-711
Publisher
Springer Nature
Online
2012-02-27
DOI
10.1007/s10549-012-1995-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity associated with lapatinib in an experimental rat model
- (2011) Umut Demirci et al. EUROPEAN JOURNAL OF CANCER
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolism considerations for kinase inhibitors in cancer treatment
- (2010) Derek R Duckett et al. Expert Opinion on Drug Metabolism & Toxicology
- Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
- (2010) W. C. Teng et al. MOLECULAR PHARMACOLOGY
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?
- (2009) JR Senior CLINICAL PHARMACOLOGY & THERAPEUTICS
- Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib
- (2009) Gianluca Tomasello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Gastrointestinal toxicities of novel agents in cancer therapy
- (2009) Amani Asnacios et al. EUROPEAN JOURNAL OF CANCER
- Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
- (2009) Brian Leyland-Jones JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
- (2009) Timothy C. Ryken et al. JOURNAL OF NEURO-ONCOLOGY
- Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4
- (2008) Shu-Feng Zhou CURRENT DRUG METABOLISM
- Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
- (2008) Henry L. Gomez et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
- (2008) Yohann Loriot et al. Nature clinical practice. Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation